 <h1>Yondelis Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>trabectedin</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about trabectedin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Yondelis.</p><h2>In Summary</h2><p><b>Common side effects of Yondelis include:</b> increased creatine phosphokinase in blood specimen, increased liver enzymes, increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase, increased serum bilirubin, and neutropenia. <b>Other side effects include:</b> febrile neutropenia, cardiomyopathy, and fever.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to trabectedin: intravenous powder for solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, trabectedin (the active ingredient contained in Yondelis) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking trabectedin:</p><p>
<i>More common</i>
</p><ul>
<li>Chest discomfort or pain</li>
<li>difficulty breathing</li>
<li>dizziness</li>
<li>faintness</li>
<li>fast irregular or pounding heartbeat</li>
<li>swelling of the feet or lower legs</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Dark-colored urine</li>
<li>fever</li>
<li>muscle cramps or spasms</li>
<li>muscle pain or stiffness</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Abdominal or stomach pain or tenderness</li>
<li>clay colored stools</li>
<li>decreased appetite</li>
<li>headache</li>
<li>itching or skin rash</li>
<li>loss of appetite</li>
<li>nausea and vomiting</li>
<li>swelling of the feet or lower legs</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Black, tarry stools</li>
<li>chills</li>
<li>cough</li>
<li>difficulty with swallowing</li>
<li>hives</li>
<li>lower back or side pain</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>sore throat</li>
<li>tightness in the chest</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unusual bleeding or bruising</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of trabectedin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
<li>difficulty having a bowel movement (stool)</li>
<li>decreased appetite</li>
<li>headache</li>
<li>trouble sleeping</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Pain at the injection site</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to trabectedin: intravenous powder for injection</i></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased ALT (up to 96.1%), increased AST (up to 89.5%), increased alkaline phosphatase (up to 70%), hyperbilirubinemia (up to 25.2%), increased gamma-glutamyltransferase (% unavailable)</p>
<p><b>Common</b> (1% to 10%): Drug-induced liver injury</p>
<p><b>Uncommon</b> (0.1% to 1%): Hepatotoxicity</p>
<p><b>Frequency not reported</b>: Hepatic failure, increased conjugated bilirubin<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (up to 96%), neutropenia (up to 91.6%), leukopenia (up to 94.9%), thrombocytopenia (up to 63.7%)</p>
<p><b>Common</b> (1% to 10%): Febrile neutropenia, neutropenic sepsis, pancytopenia, bone marrow failure, granulocytopenia</p>
<p><b>Uncommon</b> (0.1% to 1%): Neutropenic infection<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 75%), vomiting (up to 51.7%), constipation (up to 37%), diarrhea (up to 35%), stomatitis (up to 19.2%),</p>
<p><b>Common</b> (1% to 10%): Abdominal pain, dyspepsia, upper abdominal pain<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue/asthenia/malaise (up to 69%), peripheral edema (up to 28%), mucosal inflammation (up to 11.4%), pyrexia (up to 10.2%)</p>
<p><b>Common</b> (1% to 10%): Infection, edema, injection site reaction</p>
<p><b>Uncommon</b> (0.1% to 1%): Septic shock</p>
<p><b>Frequency not reported</b>: Multi-organ failure, catheter site reactions</p>
<p><b>Postmarketing reports</b>: Extravasation/tissue necrosis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypoalbuminemia (up to 63%), decreased appetite (up to 37%), anorexia (up to 28.8%)</p>
<p><b>Common</b> (1% to 10%): Dehydration, hypokalemia, decreased weight<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased creatinine (up to 46%)</p>
<p><b>Common</b> (1% to 10%): Renal failure<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Elevated creatine phosphokinase (up to 33%), arthralgia (up to 15%), myalgia (up to 12%)</p>
<p><b>Common</b> (1% to 10%): Back pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Rhabdomyolysis</p>
<p><b>Frequency not reported</b>: Musculoskeletal pain<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (up to 25%)</p>
<p><b>Common</b> (1% to 10%): Cough, pulmonary embolism</p>
<p><b>Uncommon</b> (0.1% to 1%): Pulmonary edema<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 25%)</p>
<p><b>Common</b> (1% to 10%): Peripheral neuropathy, dysgeusia, dizziness, paresthesia</p>
<p><b>Uncommon</b> (0.1% to 1%): Syncope</p>
<p><b>Frequency not reported</b>: Hypoesthesia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Palmar-plantar erythrodysesthesia (up to 24%), alopecia (up to 12%)</p>
<p><b>Common</b> (1% to 10%): Rash, skin hyperpigmentation<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (up to 15%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Cardiomyopathy, decreased ejection fraction, hypotension, flushing</p>
<p><b>Uncommon</b> (0.1% to 1%): Left ventricular dysfunction<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity reactions<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Yondelis (trabectedin)." Janssen Pharmaceuticals, Titusville, NJ. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Yondelis (trabectedin)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: alkylating agents</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Yondelis &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Soft Tissue Sarcoma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to trabectedin: intravenous powder for injection</i></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased ALT (up to 96.1%), increased AST (up to 89.5%), increased alkaline phosphatase (up to 70%), hyperbilirubinemia (up to 25.2%), increased gamma-glutamyltransferase (% unavailable)</p><p><b>Common</b> (1% to 10%): Drug-induced liver injury</p><p><b>Uncommon</b> (0.1% to 1%): Hepatotoxicity</p><p><b>Frequency not reported</b>: Hepatic failure, increased conjugated bilirubin<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (up to 96%), neutropenia (up to 91.6%), leukopenia (up to 94.9%), thrombocytopenia (up to 63.7%)</p><p><b>Common</b> (1% to 10%): Febrile neutropenia, neutropenic sepsis, pancytopenia, bone marrow failure, granulocytopenia</p><p><b>Uncommon</b> (0.1% to 1%): Neutropenic infection<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 75%), vomiting (up to 51.7%), constipation (up to 37%), diarrhea (up to 35%), stomatitis (up to 19.2%),</p><p><b>Common</b> (1% to 10%): Abdominal pain, dyspepsia, upper abdominal pain<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue/asthenia/malaise (up to 69%), peripheral edema (up to 28%), mucosal inflammation (up to 11.4%), pyrexia (up to 10.2%)</p><p><b>Common</b> (1% to 10%): Infection, edema, injection site reaction</p><p><b>Uncommon</b> (0.1% to 1%): Septic shock</p><p><b>Frequency not reported</b>: Multi-organ failure, catheter site reactions</p><p><b>Postmarketing reports</b>: Extravasation/tissue necrosis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypoalbuminemia (up to 63%), decreased appetite (up to 37%), anorexia (up to 28.8%)</p><p><b>Common</b> (1% to 10%): Dehydration, hypokalemia, decreased weight<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased creatinine (up to 46%)</p><p><b>Common</b> (1% to 10%): Renal failure<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Elevated creatine phosphokinase (up to 33%), arthralgia (up to 15%), myalgia (up to 12%)</p><p><b>Common</b> (1% to 10%): Back pain</p><p><b>Uncommon</b> (0.1% to 1%): Rhabdomyolysis</p><p><b>Frequency not reported</b>: Musculoskeletal pain<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (up to 25%)</p><p><b>Common</b> (1% to 10%): Cough, pulmonary embolism</p><p><b>Uncommon</b> (0.1% to 1%): Pulmonary edema<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 25%)</p><p><b>Common</b> (1% to 10%): Peripheral neuropathy, dysgeusia, dizziness, paresthesia</p><p><b>Uncommon</b> (0.1% to 1%): Syncope</p><p><b>Frequency not reported</b>: Hypoesthesia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Palmar-plantar erythrodysesthesia (up to 24%), alopecia (up to 12%)</p><p><b>Common</b> (1% to 10%): Rash, skin hyperpigmentation<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (up to 15%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Cardiomyopathy, decreased ejection fraction, hypotension, flushing</p><p><b>Uncommon</b> (0.1% to 1%): Left ventricular dysfunction<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity reactions<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Yondelis (trabectedin)." Janssen Pharmaceuticals, Titusville, NJ. </p><h2>More about Yondelis (trabectedin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: alkylating agents</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Yondelis &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Soft Tissue Sarcoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>